COMP <GO>
CSX vs TMO // FORWARD P/E MULTIPLE
CSX Corporation (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: CSX 8
— TMO 6
▲ FORWARD P/E MULTIPLE LEADER: CSX
LAST: $51.99 (-0.48%) • MKT CAP: $96.30B
forward-pe
31.0x
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
forward-pe
36.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CSX VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CSX | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 41.00% | 0.00 | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 17.20% | 9.30% | +7.90 | CSX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 14.9x | 30.4x | -15.50 | CSX | /valuation <GO> |
| Free Cash Flow Yield | 1.78% | 2.40% | -0.62 | TMO | /fcf-yield <GO> |
| Operating Margin | 32.10% | 17.40% | +14.70 | CSX | /operating-margins <GO> |
| Net Profit Margin | 20.50% | 15.10% | +5.40 | CSX | /net-margins <GO> |
| Revenue Growth (YoY) | -3.10% | 3.90% | -7.00 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.01% | 0.24% | +0.77 | CSX | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.88 | 4.50 | -1.62 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.70% | -0.20 | CSX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 67.5 | 59.1 | +8.36 | CSX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.94 | -0.06 | TMO | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 31.0x | 36.3x | -5.30 | CSX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $96.30B | $262.22B | -$165.92B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CSX REV | TMO REV | CSX GROSS % | TMO GROSS % | CSX FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $14.09B | $44.56B | 44.0% | 44.0% | $1.71B | $6.29B |
| FY 2024 | $14.54B | $42.88B | 44.0% | 44.0% | $2.72B | $7.27B |
| FY 2023 | $14.66B | $42.86B | 44.0% | 44.0% | $4.85B | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CSX // BETA 0.88
TMO // BETA 0.94